We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

203 hedge funds and large institutions have $3.89B invested in Blueprint Medicines in 2019 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 66 increasing their positions, 59 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

410% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 10

60% more capital invested

Capital invested by funds: $2.42B → $3.89B (+$1.46B)

57% more funds holding in top 10

Funds holding in top 10: 7 → 11 (+4)

25% more funds holding

Funds holding: 162 → 203 (+41)

12% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 59

6.03% more ownership

Funds ownership: 104.04% → 110.07% (+6%)

12% less call options, than puts

Call options by funds: $15.1M | Put options by funds: $17.1M

Holders
203
Holders Change
+41
Holders Change %
+25.31%
% of All Funds
4.39%
Holding in Top 10
11
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+57.14%
% of All Funds
0.24%
New
51
Increased
66
Reduced
59
Closed
10
Calls
$15.1M
Puts
$17.1M
Net Calls
-$1.98M
Net Calls Change
-$5.08M

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$30.6M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$26.1M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$25.6M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$21.9M
5
MWNA
Marshall Wace North America
New York
+$19.5M

Top Sellers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
-$40M
2
PHS
PFM Health Sciences
California
-$37.4M
3
Morgan Stanley
Morgan Stanley
New York
-$15M
4
State Street
State Street
Massachusetts
-$14.7M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
-$13.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
26
Victory Capital Management
Texas
$37.8M +$157K +2,120 +0.5%
FCMI
27
Foresite Capital Management III
California
$37.4M – – –
Westfield Capital Management
28
Westfield Capital Management
Massachusetts
$37.4M -$8.56M -115,785 -20%
EAM
29
Eventide Asset Management
Massachusetts
$37M +$3.69M +50,000 +12%
CAM
30
Cormorant Asset Management
Massachusetts
$36M +$6.55M +88,649 +25%
Goldman Sachs
31
Goldman Sachs
New York
$32.2M +$6.02M +81,458 +25%
Loomis, Sayles & Company
32
Loomis, Sayles & Company
Massachusetts
$29.7M +$988K +13,372 +4%
American Century Companies
33
American Century Companies
Missouri
$26.8M +$4.66M +63,098 +23%
VOYA Investment Management
34
VOYA Investment Management
Georgia
$26.4M -$3.77M -51,047 -13%
RSCM
35
Rock Springs Capital Management
Maryland
$22M +$4.53M +61,342 +29%
MWNA
36
Marshall Wace North America
New York
$21.1M +$19.5M +263,648 New
LCM
37
Laurion Capital Management
New York
$21M +$19.4M +261,904 New
Charles Schwab
38
Charles Schwab
California
$19.7M +$641K +8,673 +4%
GTC
39
Ghost Tree Capital
New York
$19.2M +$17.7M +240,000 New
Brown Advisory
40
Brown Advisory
Maryland
$19M +$17.5M +237,372 New
CCM
41
Cadian Capital Management
New York
$16M +$14.8M +200,000 New
CH
42
CVI Holdings
Delaware
$16M +$14.8M +200,000 New
Bank of New York Mellon
43
Bank of New York Mellon
New York
$15.5M +$890K +12,048 +7%
Jennison Associates
44
Jennison Associates
New York
$15.1M +$15.4K +209 +0.1%
Alyeska Investment Group
45
Alyeska Investment Group
Illinois
$13.6M +$12.5M +169,505 New
Deutsche Bank
46
Deutsche Bank
Germany
$13M +$971K +13,142 +9%
MIM
47
Monashee Investment Management
Massachusetts
$11.1M +$10.2M +138,500 New
UBS AM
48
UBS AM
Illinois
$10.4M +$327K +4,419 +4%
OM
49
Opaleye Management
Massachusetts
$10.4M -$12.6M -170,000 -57%
DCM
50
Driehaus Capital Management
Illinois
$10.3M +$8.08M +109,336 +576%
1
2
3 4 5

BPMC Hedge Fund Activity: Q1 2019 in Review

203 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2019, worth a combined $3.89B — up 60% from $2.42B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new BPMC positions and 10 closed out — a net gain of 41 holders — while 66 added to existing stakes and 59 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $30.6M. The largest seller was Viking Global Investors, cutting an estimated $40M.

  • 203 institutional investors held Blueprint Medicines (BPMC) as of Q1 2019, up from 162 in Q4 2018.
  • Funds reported $3.89B of Blueprint Medicines stock for Q1 2019, up 60% quarter-over-quarter.
  • 51 funds opened new Blueprint Medicines positions in Q1 2019 and 10 closed out, a net change of +41 holders.
  • The largest Blueprint Medicines buyer in Q1 2019 was Perceptive Advisors, an estimated $30.6M added.
  • The largest Blueprint Medicines seller in Q1 2019 was Viking Global Investors, an estimated $40M sold.

Based on aggregated 13F filings for Q1 2019.